Home » AGEB Journal » Issues » Volume 83" » Fasc.4 - Case series » Article details

Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises

Journal Volume 83 - 2020
Issue Fasc.4 - Case series
Author(s) S. Leclercq 1 2, P. de Timary 1 3, P. Stärkel 4 5
Full article
Full Article
PAGES 616-621
VIEW FREE PDF
Affiliations:
(1) Institute of Neuroscience, Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium
(2) Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium
(3) Department of Adult Psychiatry, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium
(4) Institute of Experimental and Clinical Research, Laboratory of Hepato-gastroenterology, Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium
(5) Department of Hepato-gastroenterology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium

The human intestine is colonized by a variety of microbes that influence the metabolic responses, the immune system and the nervous system. Dietary patterns are important factors that shape the composition of the gut microbiota. Many animal models of alcohol exposure have highlighted the key role of the alcohol-induced gut microbiota alterations, leaky gut and translocation of microbial products in the development of alcoholic liver disease (ALD). However, in humans, there is no clear picture defining an “alcoholic microbiome”, and the link between intestinal dysbiosis and ALD development is far from being understood. Although we do not comprehend all the mechanistic insights, clinical studies aiming at modulating the gut microbiota of alcoholic patients have shown some beneficial effects. Here we review the potential therapeutic effects of probiotics in ALD and give some clinical perspectives on the role of prebiotics and the use of fecal microbiota transplantation.

Keywords: gut microbiota, alcoholic liver disease, probiotics, prebiotics, fecal microbiota transplantation, metabolomics.

The authors declare that they have no conflict of interest.
© Acta Gastro-Enterologica Belgica.
PMID 33321019